Early versus late initiation of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis
Annals of Middle Eastern Medicine · 26.10.2026 · 2 (5) · 697-708
DOI: 10.24911/amem.15-3116 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Annals of Middle Eastern Medicine, online erschienen am 26.10.2026. Verfasst von Lara Mohammed Aljohani und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Relapsing-remitting multiple sclerosis (RRMS) is a chronic immune-mediated disorder of the central nervous system associated with recurrent inflammatory activity and long-term disability accumulation. Although escalation therapy has traditionally been used, early initiation of high-efficacy disease-modifying therapies (HE-DMTs) may provide stronger inflammatory control and improve long-term outcomes.
Objective
This systematic review and meta-analysis aimed to compare early initiation of HE-DMTs with escalation or delayed treatment strategies in adults with relapsing-remitting MS.
Methods
PubMed, Scopus, and Web of Science were systematically searched. Eligible studies included adults with RRMS treated with either early HE-DMTs or escalation/delayed strategies. Outcomes included annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS) change, and delta-Expanded Disability Status Scale (ΔEDSS). Study quality was assessed using the Newcastle-Ottawa Scale, and pooled analyses were performed using random-effects models.
Results
Ten observational cohort studies were included. Early initiation of high-efficacy treatment was associated with a lower ARR than escalation therapy. Disability findings remained uncertain. The pooled EDSS-change analysis was not statistically significant and showed considerable heterogeneity. Only one eligible study reported an adjusted ΔEDSS comparison; therefore, this outcome was reported narratively and was not meta-analyzed. Nonrandom treatment allocation and potential confounding by indication limit causal interpretation.
Conclusion
Early initiation of high-efficacy disease-modifying therapy was associated with lower relapse activity in observational RRMS cohorts. The available disability evidence does not establish a causal advantage of either treatment strategy and requires cautious interpretation.
Zitieren
APA
Aljohani, L. M., Alsarrawi, D. J., Zayed, R. M., Almutairi, S. A., Alzahrani, R. S., Almutiri, S. S., Taha, O. O., Alanazi, S. A., & Ali, W. (2026). Early versus late initiation of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis. Annals of Middle Eastern Medicine, 2(5), 697-708. https://doi.org/10.24911/amem.15-3116
Vancouver
Aljohani LM, Alsarrawi DJ, Zayed RM, Almutairi SA, Alzahrani RS, Almutiri SS, et al. Early versus late initiation of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis. Annals of Middle Eastern Medicine. 2026;2(5):697-708. doi:10.24911/amem.15-3116
BibTeX
@article{Aljohani2026,
author = {Aljohani, Lara Mohammed and Alsarrawi, Dimah Jalal and Zayed, Raghad Mohammed and Almutairi, Shahd Abdullah and Alzahrani, Ruof Saadallah and Almutiri, Shaden Sultan and Taha, Ola Obeid and Alanazi, Sama Abdullah and Ali, Waqar},
title = {Early versus late initiation of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis},
journal = {Annals of Middle Eastern Medicine},
year = {2026},
volume = {2},
number = {5},
pages = {697--708},
doi = {10.24911/amem.15-3116}
}
EUVIMED